{"url_path":"/sec/advb/8-k/2026-06-30/item-1-01","section_key":"item-1-01","section_title":"Item 1.01 Entry into a Material Definitive Agreement.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-30","source_url":"https://www.sec.gov/Archives/edgar/data/1941029/0001213900-26-073735-index.html","accession_number":"0001213900-26-073735","cik":"0001941029","ticker":"ADVB","issuer_name":"Advanced Biomed Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1941029/0001213900-26-073735-index.html","primary_entity_key":"0001941029","primary_entity_name":"Advanced Biomed Inc."},"word_count":299,"has_tables":true,"body_markdown":"**Item 1.01 Entry into a Material Definitive Agreement.**\n\n \n\nOn June 30, 2026, Advanced Biomed Inc. (the\n“Company”) entered into a Share Purchase Agreement (the “Agreement”) with an unrelated third party, pursuant\nto which the Company agreed to sell 100% of the issued and outstanding shares of Advanced Biomed Inc. (Taiwan), a company organized\nunder the laws of Taiwan (the Republic of China) and a wholly-owned subsidiary of the Company (the “Taiwan Subsidiary”),\nfor an aggregate purchase price of US$490,000, subject to the terms and conditions set forth in the Agreement. The transaction is expected to close within\nthree (3) months from the date of the Agreement.\n\n \n\nThe Taiwan Subsidiary conducts the Company’s\nbiomedical research and development operations, including the A+PerfusC integrated perfusion 3D cell culture platform. Following completion\nof the transaction, the Company will continue to operate its remaining businesses, including the AI-focused operations conducted through\nAcellent Technologies (Hong Kong) Co. Limited.\n\n \n\nThe foregoing description of the Agreement does\nnot purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, a copy of which is filed as\nExhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.\n\n \n\n**Forward-Looking Statements.**\n\n \n\nThis Current Report on Form 8-K contains forward-looking\nstatements within the meaning of the federal securities laws. Forward-looking statements are not guarantees of future performance and\ninvolve risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Factors that could\ncause actual results to differ include, among others, the satisfaction of closing conditions, the Company’s strategic direction\nand operations following the Disposition, and the other factors discussed in the Company’s filings with the SEC. The Company undertakes\nno obligation to publicly update any forward-looking statement except as required by law."}